International Journal of Hematology

DOI: 10.1532/IJH97.A30510 Pages: 328-330

Successful Eradication of Relapsed Primary Effusion Lymphoma with High-Dose Chemotherapy and Autologous Stem Cell Transplantation in a Patient Seronegative for Human Immunodeficiency Virus

1. Soon Chun Hyang University College of Medicine, Division of Hematology-Oncology, Department of Internal Medicine

2. Soon Chun Hyang University College of Medicine, Departments of Pathology

Correspondence to:
Hee-Sook Park
Tel: 82-2-709-9185
Fax: 82-2-709-9200



Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonim-munosuppressed patients. Patients present with lymphomatous effusions in serous cavities—pleura, pericardium, or peritoneum–without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge